Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8101 to 8132 of 8132 results

  1. Ivosidenib with azacitidine for untreated acute myeloid leukaemia with an IDH1 R132 mutation [ID6198]

    In development [GID-TA11167] Expected publication date: 04 June 2024

    Technology appraisal guidance
    In development

  2. Drug eluting stents for treating coronary heart disease: late stage assessment

    In development [GID-HTE10039] Expected publication date: TBC

    Health technology evaluations
    In development

  3. News

    Tests could lead to fewer people having unnecessary chemotherapy after surgery for early breast cancer More people with early breast

  4. NICE

    NICE helps practitioners and commissioners get the best care to patients, fast, while ensuring value for the taxpayer.

  5. Dabrafenib with trametinib for treating BRAF V600E mutation-positive glioma in children and young people aged 1 year and over [ID5104]

    In development [GID-TA11006] Expected publication date: 29 May 2024

    Technology appraisal guidance
    In development

  6. Tafamidis for treating transthyretin amyloidosis with cardiomyopathy [ID6327]

    In development [GID-TA11389] Expected publication date: 19 June 2024

    Technology appraisal guidance
    In development

  7. Atezolizumab for untreated advanced or recurrent non-small cell lung cancer when platinum-doublet chemotherapy is unsuitable [ID6218]

    In development [GID-TA11139] Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Cor-Knot for tying suture knots in valve surgery

      Status ...

    Medical technologies guidance
    Topic selection

  9. TUC Safety Valve to prevent balloon inflation in the urethra during transurethral catheterisation

      Status ...

    Medical technologies guidance
    Topic selection

  10. Cytokine adsorption technologies for treating respiratory failure in people with COVID-19

      Status ...

    Medical technologies guidance
    Topic selection

  11. Multiple sclerosis (relapsing, remitting, highly active) - natalizumab and Tyruko (natalizumab biosimilar) (after disease modifying therapy) [ID6369]

    In development [GID-TA10977] Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Archimedes for biopsy of suspected lung cancer

      Status ...

    Medical technologies guidance
    Topic selection

  13. Abaloparatide for treating osteoporosis in postmenopausal women [ID882]

    In development [GID-TA10071] Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. SQ HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites (review of TA834) [ID6280]

    In development [GID-TA11355] Expected publication date: 09 July 2024

    Technology appraisal guidance
    In development

  15. Heart failure algorithms for remote monitoring in people with cardiac implantable electronic device

    In development [GID-DG10080] Expected publication date: 22 August 2024

    Diagnostics guidance
    In development

  16. Endometriosis: diagnosis and management - diagnosing endometriosis

    In development [GID-NG10392] Expected publication date: 10 July 2024

    NICE guideline
    In development

  17. Kidney Cancer

    In development [GID-NG10398] Expected publication date: TBC

    NICE guideline
    In development

  18. Novel home-testing devices for diagnosing obstructive sleep apnoea/hypopnoea syndrome

    In development [GID-DG10074] Expected publication date: 11 September 2024

    Diagnostics guidance
    In development

  19. Trastuzumab deruxtecan for treating HER2-mutated unresectable or metastatic non-squamous non-small-cell lung cancer after 1 or more therapies [ID3934]

    Awaiting development [GID-TA10814] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  20. Upadacitinib for treating giant cell arteritis [ID6299]

    Awaiting development [GID-TA11330] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  21. Actim Pancreatitis for diagnosing acute pancreatitis

      Status ...

    Diagnostics guidance
    Topic selection

  22. CFHealthHub for managing cystic fibrosis during the COVID-19 pandemic

      Status ...

    Medical technologies guidance
    Topic selection

  23. PCONUS2 Bifurcation Aneurysm Implant for complex intracranial aneurysms

      Status ...

    Medical technologies guidance
    Topic selection

  24. Spartan RX point-of-care CYP2C19 test

      Status ...

    Diagnostics guidance
    Topic selection

  25. Healthy.io test for home testing of urine albumin to creatinine ratio

      Status ...

    Diagnostics guidance
    Topic selection

  26. FebriDx for C-reactive protein and myxovirus resistance protein A testing

      Status ...

    Diagnostics guidance
    Topic selection

  27. Helge for detecting haemolysis

      Status ...

    Diagnostics guidance
    Topic selection

  28. MolecuLight i:X for wound imaging

    The panel agreed the technology is not appropriate to be selected for guidance development as there is insufficient evidence.   ...

    Medical technologies guidance
    Topic selection

  29. NATROX oxygen wound therapy for managing diabetic foot ulcers and complex or chronic non-healing wounds

      Status ...

    Medical technologies guidance
    Topic selection

  30. Pneumonia: diagnosis and management (update)

    In development [GID-NG10357] Expected publication date: TBC

    NICE guideline
    In development

  31. Mirikizumab for treating moderately to severely active Crohn's disease ID6244

    In development [GID-TA11267] Expected publication date: TBC

    Technology appraisal guidance
    In development

  32. Heart failure algorithms for remote monitoring in people with cardiac implantable electronic device: diagnostics consultation

    We are listening to your views on this Diagnostics guidance. Comments close 4 June 2024.

    Diagnostics guidance
    In consultation